Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2017

View Archived Issues

EMA grants orphan drug designation for DCC-2618 as treatment of gastrointestinal stromal tumors

MLR-1019 ameliorates dyskinesia and neuron bursting in Parkinsonian rats

FDA accepts IND for CTLA-4 Probody therapeutic from BMS and CytomX

Axsome Therapeutics announces new product candidate for treatment of migraine

Vedanta in new and expanded collaborations to support microbiome work in cancer immunotherapy

Nippon Chemiphar completes phase I trial of NC-2500 and preclinical studies with NC-2700

Idera Pharmaceuticals' IMO-2125 awarded FDA fast track designation

FDA gives orphan drug designation to Amphivena Therapeutics' AMV-564

Melinta Therapeutics to acquire infectious disease business from The Medicines Company

Aptinyx tests PTSD candidate NYX-783 in animal models

Zogenix begins phase III study of ZX-008 in Lennox-Gastaut syndrome

Researchers develop mouse model of coronary collateral vessel growth

Peptide anti-PCSK9 vaccine shows promise for treating dyslipidemia

EMA gives orphan drug designation to ProQR Therapeutics' QR-313

HanAll initiates phase II trial of HL-036 to treat signs and symptoms of dry eye

ID Pharma submits CTN in Japan for DiscGenics' IDCT-001 clinical trial

Cambridge Enterprise, Sydney Children's Hospitals Network design viral vectors encoding factor I

Idorsia Pharmaceuticals patents novel antibacterials

Lilly identifies novel beta-secretase 1 inhibitors

Researchers present SUVN-1603054, a novel antipsychotic for treating schizophrenia

Novel soluble guanylate cyclase activators discovered at Merck & Co.

Istituto Europeo di Oncologia Srl synthesizes new lysine-specific demethylase 4C inhiibitors

First pediatric patient dosed in phase I/II study of AEB-1102 in arginase 1 deficiency

Regeneron and Decibel collaborate to develop therapeutics for hearing loss

Pharnext gives update on phase III PLEO-CMT study

Sanofi updates information on Dengvaxia

TherapeuticsMD resubmits NDA for TX-004-HR for dyspareunia

ViiV initiates phase III study of long-acting cabotegravir for prevention of HIV infection in women

AstraZeneca studies AZD-5718 in patients with coronary artery disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...